

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

BAUSCH HEALTH IRELAND LIMITED,

Patent Owner.

Case IPR2022-00722
U.S. Patent No. 7,041,786

DECLARATION OF STEPHEN G. DAVIES, D.PHIL.

Table of Contents

I. INTRODUCTION 1

II. QUALIFICATIONS AND BACKGROUND 2

 A. Education and Experience 2

 B. Documents and Information Considered in Forming Opinions 6

 C. Scope of Work and Compensation 7

 D. Expert Testimony in the Last Four Years 8

III. INSTITUTED GROUNDS OF UNPATENTABILITY 8

IV. LEGAL STANDARDS 9

V. A PERSON OF ORDINARY SKILL IN THE ART 13

VI. SUMMARY OF OPINIONS 14

VII. TECHNICAL BACKGROUND 16

 A. The Gastrointestinal Tract 18

 B. Naturally Occurring Peptides as Agonists for Guanylate Cyclase
 C Receptors 21

 1. Topoisomerism 22

 2. Uroguanylin 28

 3. Guanylin 40

 4. Heat-Stable Enterotoxins 41

 C. Development of Therapeutic Peptides Was Unpredictable 50

 D. By January 2002, the Art had Confirmed the Importance of
 Maintaining Asp at Position 3 of Uroguanylin 58

VIII. PLECANATIDE AND THE '786 PATENT 60

 A. U.S. Patent No. 7,041,786 60

IX. GROUND 1: CLAIM 1 WOULD NOT HAVE BEEN OBVIOUS OVER CURRIE AND LI	62
A. A Person of Ordinary Skill in the Art Would Have Been Disincentivized from Selecting Human Uroguanylin as a Lead Compound	62
1. Human uroguanylin was known to suffer from interconverting topoisomers.....	63
a. The impact of interconversion on manufacturing and formulation.....	64
b. Interconversion <i>in vivo</i>	66
2. Because the heat-stable enterotoxins (STs) did not have the drawbacks from topoisomerism, were more stable, and had better overall activity profile, they would have been the clear lead compound to be selected for further development.....	69
B. A Person of Ordinary Skill in the Art Would Not Have Been Motivated to Substitute Asp ³ with Glu ³ with Any Expectation of Yielding a Peptide with Improved Properties.....	72
1. Nothing in the art suggested substituting Asp ³ for Glu ³ would have stopped human uroguanylin’s interconversion	72
2. Nothing in the art suggested that substituting Asp ³ for Glu ³ would have reasonably been expected to improve the resulting peptide’s activity.....	74
a. Conservative substitutions would not have been expected to improve activity.....	75
b. As of the priority date, the art taught that Asp at positions 2 and 3 was required for clinical effect.....	80
c. Protonation would not have been expected to improve activity	86

d.	Dr. Peterson overstates the benefit of avoiding or removing aspartimide formation because the art taught other, routinely used means for doing so	98
3.	Unexpected Superior Results Underscore the Lack of any Reasonable Expectation of Success and Reinforce the Nonobviousness of Plecanatide	100
a.	Unexpected stabilization against interconversion	101
b.	Unexpected superior potency for cGMP Production	105
c.	Unexpectedly higher heat stability	114
d.	Unexpectedly better (and lower) IC ₅₀ indicative of the claimed invention's superior activity	118
X.	GROUND 2: CLAIMS 2, 4, AND 5 WOULD NOT HAVE BEEN OBVIOUS OVER CURRIE, LI, AND NARAYANI.....	120
XI.	GROUND 3: CLAIMS 3-5 WOULD NOT HAVE BEEN OBVIOUS OVER CURRIE, LI, NARAYANI, AND CAMPIERI.....	121
XII.	GROUND 4: CLAIM 6 WOULD NOT HAVE BEEN OBVIOUS OVER CURRIE, LI, AND EKWURIBE.....	122
XIII.	CONCLUSION.....	122

I. INTRODUCTION

1. I have been retained by counsel for Patent Owner Bausch Health Ireland Limited (“Bausch”¹) as an expert in the fields of organic and medicinal chemistry, in connection with the above-captioned *inter partes* review proceeding.

2. I have been asked to provide my opinion regarding Petitioner Mylan Pharmaceuticals Inc.’s (“Mylan”) asserted grounds of unpatentability for claims 1-6 of U.S. Patent No. 7,041,786. (Ex. 1001.)²

3. I have also been asked to respond to the Declaration of Blake R. Peterson, Ph.D., submitted in this proceeding on behalf of Mylan. (See Ex. 1002.)³ More specifically, I have considered Dr. Peterson’s opinions regarding whether claims 1-6 of the ’786 patent are unpatentable as obvious.

4. As explained below, it is my opinion that the inventions of claims 1-6 would have been non-obvious to a person of ordinary skill in the art on or before January 17, 2002.

¹ I understand that Bausch acquired the ’786 patent from Synergy Pharmaceuticals, Inc. In my declaration, I use Bausch to also refer to Synergy Pharmaceuticals, Inc.

² U.S. Patent No. 7,041,786 (“the ’786 patent”).

³ Declaration of Blake R. Peterson. (“the Peterson Declaration”).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.